MedTrace Logo

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly

NCT07623824 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2026-06-03

No results posted yet for this study

Summary

he purpose of this study is to evaluate the efficacy and safety of SYHX2008 injection in in patients with acromegaly.

Conditions

  • Diagnosed With Acromegaly, Currently in the Active Stage of the Disease

Interventions

DRUG

SYHX2008

The patients will accept SYHX2008 injection by subcutaneous administration.A treatment period of 28 weeks.

DRUG

Sandostatin LAR®

The patients will accept Sandostatin LAR@ by intra-muscular administration.A treatment period of 28 weeks.

Sponsors & Collaborators

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2029-07-31
Completion
2029-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07623824 on ClinicalTrials.gov